Fulvestrant +/− Ganetespib for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on other treatments intended to treat your cancer while participating. You must also be at least 2 weeks from your last chemotherapy or radiotherapy.
What data supports the effectiveness of the drug Fulvestrant for breast cancer?
Fulvestrant has been shown to be effective in treating advanced breast cancer in postmenopausal women, with studies indicating it is at least as effective as other treatments like anastrozole. It has demonstrated a clinical benefit rate of 29.9% in heavily pretreated patients, showing its potential as a valuable option for those who have progressed on prior therapies.12345
Is Fulvestrant safe for use in humans?
How is the drug Fulvestrant unique for treating breast cancer?
What is the purpose of this trial?
Ganetespib is a drug that may stop cancer cells from growing. This drug has been used in other research studies and laboratory experiments. It has also been studied in phase I trials, where the appropriate dosing has been determined. Ganetespib is considered an "HSP90 inhibitor". By blocking HSP90, ganetespib is thought to reduce the ability of cancer cells to become resistant to treatment.Fulvestrant is a hormonal therapy that works by attaching to estrogen receptors. In doing so, it can block the effect of estrogen on cancer cells. In addition, fulvestrant causes a decrease in the number of estrogen receptors. Fulvestrant is a drug that is approved by the FDA for treatment of metastatic, hormone receptor positive breast cancer, based upon the results of phase III clinical trials.In the laboratory, adding ganetespib to fulvestrant appears to improve its effectiveness. It is not known whether this is true in humans. In this research study, we are evaluating the effect of the addition of ganetespib to fulvestrant in participants with hormone receptor-positive, metastatic breast cancer.
Research Team
Nancy U Lin, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for individuals with hormone receptor-positive, metastatic breast cancer that's HER2 negative. Participants can have had one prior chemotherapy treatment and must have measurable disease. They should be in good physical condition (ECOG status of 0 or 1) and not currently pregnant or breastfeeding. Those who've previously used fulvestrant or HSP90 inhibitors, have untreated brain metastases, other recent cancers, or severe illnesses are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Fulvestrant with or without Ganetespib. Fulvestrant is administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; Ganetespib is administered intravenously on days 1, 8, and 15 of each 28-day cycle.
Follow-up
Participants are monitored for safety and effectiveness after treatment. Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles thereafter. Participants were followed for survival up to 4 years from treatment end.
Treatment Details
Interventions
- Fulvestrant
- Ganetespib
Fulvestrant is already approved in European Union, United States, Canada, Japan for the following indications:
- Hormone receptor-positive metastatic breast cancer
- Locally advanced breast cancer
- Hormone receptor-positive metastatic breast cancer
- Locally advanced breast cancer
- Hormone receptor-positive metastatic breast cancer
- Locally advanced breast cancer
- Hormone receptor-positive metastatic breast cancer
- Locally advanced breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor